Regenerative medicine company Avita Medical Inc. raised AU$23 million (US$15 million) through a private placement on the Australian Securities Exchange (ASX:AVH) to support growth of its Recell therapeutic acute wound portfolio. Funds raised will support continued growth of the company’s therapeutic acute wound portfolio and will cover operations through 2026.

Med-tech companies brought in $18.11 billion through financings in the first seven months of 2025, marking a modest rebound from the sector’s recent lows. The total surpasses the $11.73 billion raised during the same period in 2023 and slightly edged out the $16.59 billion raised in the same period in 2024.

With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, biopharma companies are building treasuries of digital assets to secure future R&D efforts and operational runways. Companies such as Artelo Biosciences Inc., MEI Pharma Inc., Windtree Therapeutics Inc. and 180 Life Sciences Corp. and have entered crypto deals in recent weeks, with the latter noting the potential to “unlock value outside traditional biotech milestones.”